Overview

Lispro Mix 25 vs. Glargine in Type 2 Diabetics

Status:
Completed
Trial end date:
2003-07-01
Target enrollment:
Participant gender:
Summary
In patients with type 2 diabetes who have not been on insulin therapy before the study will achieve better glycemic control by the treatment regiment consisting of two times daily insulin lispro mix 25 than by the treatment regiment with consisting of one time daily injection of insulin glargine. Improved glycemic control will be compared by the fasting plasma glucose and blood glucose excursions 2 hours after breakfast.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Hypoglycemic Agents
Insulin
Insulin Glargine
Insulin Lispro
Insulin, Globin Zinc